Gyre Therapeutics (GYRE) Other Non-Current Assets (2011 - 2026)

Gyre Therapeutics (GYRE) has 16 years of Other Non-Current Assets data on file, last reported at $4.9 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $4.9 million, down 11.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.9 million (down 11.05% YoY), and the FY2025 annual result was $5.0 million, up 66.6% from the prior year.
• Other Non-Current Assets fell to $4.9 million in Q1 2026 per GYRE's latest filing, from $5.0 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $5.6 million in Q1 2025 and troughed at $168000.0 in Q2 2022.
• A 5-year average of $2.3 million and a median of $1.3 million in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets sank 85.63% in 2022, then surged 1546.43% in 2024.
• A 5-year view of Other Non-Current Assets shows it stood at $3.4 million in 2022, then slumped by 70.68% to $995000.0 in 2023, then surged by 204.52% to $3.0 million in 2024, then surged by 66.6% to $5.0 million in 2025, then retreated by 2.1% to $4.9 million in 2026.
• Business Quant data shows GYRE's Other Non-Current Assets at $4.9 million in Q1 2026, $5.0 million in Q4 2025, and $5.3 million in Q3 2025.